JW Ther­a­peu­tics hauls in $300M IPO just as liso-cel-in­spired CAR-T nears the fin­ish line in Chi­na

Close to two years af­ter Juno Ther­a­peu­tics dis­ap­peared from Nas­daq, a CAR-T biotech it spawned is set­tling on a stock ex­change on the oth­er side of the globe.

JW Ther­a­peu­tics, a joint ven­ture be­tween Juno and WuXi AppTec, raised $300 mil­lion in its IPO on the Hong Kong Stock Ex­change — build­ing on $190 in ven­ture mon­ey since launch­ing in 2018.

The pitch is all about bring­ing cell ther­a­py break­throughs to Chi­na, tap­ping in­to Amer­i­can con­nec­tions that ex­tend in­to Lyell, a new start­up led by Juno co-founder Rick Klaus­ner, and Eu­re­ka, a long­time part­ner of Juno. WuXi, a glob­al CRO, brings ex­per­tise in process de­vel­op­ment and man­u­fac­tur­ing to the mix.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER